Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for posttraumatic stress disorder (PTSD). For more information, please visit www.recoverystudy.com or www.clinicaltrials.gov (NCT03841773).

SEC Filings
: All SEC Filings

All SEC Filings

Filter Filings:
Date Form Description Docs XBRL Pages
02/14/19 SC 13G/A Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions 6
02/13/19 SC 13G/A Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions 10
01/07/19 SC 13G/A Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions 15
12/20/18 SC 13G Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions
Related Documents
14
12/19/18 SC 13G Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions 15
12/18/18 8-K Current report filing
Related Documents
5
12/14/18 SC 13G Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions
Related Documents
10
12/14/18 SC 13G Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions 10
12/11/18 8-K Current report filing 102
12/10/18 424B4 Prospectus filed pursuant to Rule 424(b)(4) 42